(CONVENIENCE TRANSLATION OF THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH)

MLP SAĞLIK HİZMETLERİ A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED 1 JANUARY- MARCH 31, 2022

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 1 JANUARY - MARCH 31, 2022

INDEX		PAGE
CONSOL	IDATED INTERIM STATEMENT OF FINANCIAL POSITION	1-2
	IDATED INTERIM STATEMENT OF PROFIT OR LOSS HER COMPREHENSIVE INCOME	3
CONSOL	IDATED INTERIM STATEMENT OF CHANGES IN EQUITY	4
CONSOL	IDATED INTERIM STATEMENT OF CASH FLOWS	5-6
NOTES T	TO THE CONSOLIDATED FINANCIAL STATEMENTS	7-43
NOTE 1	ORGANIZATION AND OPERATIONS OF THE GROUP	
NOTE 2	BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS	
NOTE 3	RELATED PARTY DISCLOSURES	
NOTE 4	CASH AND CASH EQUIVALENTS	
NOTE 5	FINANCIAL INSTRUMENTS	
NOTE 6	TRADE RECEIVABLES AND PAYABLES	
NOTE 7	OTHER RECEIVABLES AND PAYABLES	
NOTE 8	INVENTORIES	
NOTE 9	PREPAID EXPENSES AND DEFERRED INCOME	
NOTE 10	PROPERTY, EQUIPMENT AND OTHER INTANGIBLE ASSETS	
NOTE 11	RIGHT OF USE ASSETS	
NOTE 12	PAYABLES FOR EMPLOYEE BENEFITS	
NOTE 13	OTHER ASSETS AND LIABILITIES	
NOTE 14	PROVISIONS	
NOTE 15	COMMITMENTS	
NOTE 16	SHARE CAPITAL/OTHER RESERVES	
NOTE 17	REVENUE	
NOTE 18	OPERATING EXPENSES	
NOTE 19	OTHER INCOME AND EXPENSE FROM OPERATING ACTIVITIES	
NOTE 20	INCOME AND EXPENSES FROM INVESTING ACTIVITIES	
NOTE 21	FINANCE EXPENSES	
NOTE 22	TAXES ON INCOME (DEFERRED TAX ASSET AND LIABILITIES INCLUDED)	
NOTE 23	EARNINGS PER SHARE	
NOTE 24	FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES	
NOTE 25	EVENTS AFTER THE REPORTING PERIOD	

APPENDIX I EARNINGS BEFORE INTEREST TAXES DEPRECIATION AND AMORTISATION ("EBITDA")

CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION AS AT MARCH 31, 2022 (Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Unaudited March 31, 2022	Audited December 31, 2021
Assets			
Current Assets:		3,102,314	2,741,333
Cash and cash equivalents	4	649,699	680,241
Trade receivables	6	1,634,103	1,318,054
- Due from related parties	3	2,798	194
- Trade receivables from third parties		1,631,305	1,317,860
Other receivables	7	127,304	117,757
- Due from related parties	3	73,912	54,805
- Other receivables from third parties		53,392	62,952
Inventories	8	342,105	285,276
Prepaid expenses	9	260,286	263,408
Other current assets	13	88,817	76,597
Non-current Assets:		3,164,137	3,006,788
Trade receivables		1,053	1,053
Other receivables	7	4,400	3,876
Property plant and equipment	10	1,056,945	1,014,733
Intangible assets		699,812	701,739
- Goodwill		38,661	38,661
- Other intangible assets	10	661,151	663,078
Right of use assets	11	605,947	539,308
Prepaid expenses	9	351,456	324,183
Deferred tax assets	22	444,560	421,896
TOTAL ASSETS		6,266,487	5,748,121

CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Unaudited March 31, 2022	Audited December 31, 2021
Liabilities and equity			
Current Liabilities:		3,746,822	3,318,172
Short term borrowings		499,992	568,744
Short term portion of long term borrowings	5	456,676	437,463
Obligations under finance leases	5	119,785	128,112
Short term lease liabilities	5	182,756	139,932
Trade payables	6	1,792,892	1,546,337
- Due to related parties	3	27,890	35,595
- Trade payables to third parties		1,757,002	1,510,742
Payables related to employee benefits	12	132,565	100,417
Other payables	7	78,883	64,967
- Due to related parties	3	799	799
- Other payables to third parties		78,084	64,168
Deferred income	9	375,806	243,730
Short term provisions		76,124	52,807
- Short term provisions for employment benefits	12	32,497	23,779
- Other short term provisions	14	43,627	29,028
Current tax liabilities	22	39,343	35,663
Non-current Liabilities:		1,655,901	1,760,752
Long term borrowings	5	507,596	619,594
Obligations under finance leases	5	84,557	102,445
Long term lease liabilities	5	782,743	752,859
Other payables		89,261	93,102
- Other payables to third parties	7	89,261	93,102
Deferred income	9	15,718	18,374
Long term provisions	-	46,891	37,944
- Long term provisions for employee benefits	12	46,891	37,944
Deferred tax liabilities	22	129,135	136,434
2011		·	·
EQUITY:		863,764	669,197
Equity Attributable to the Owner of the Company:		703,290	538,636
Share capital	16	208,037	208,037
Share premium	16	556,162	556,162
Other comprehensive income or expenses that will not be reclassified			,
subsequently to profit or loss		(45,228)	(43,569)
- Accumulated gain/(loss) on remeasurement of		(.5,225)	(13,507)
defined benefit plans		(45,228)	(43,569)
Restricted reserves	16	10,260	10,260
Accumulated deficit	10	(195,978)	(482,677)
Net profit for the period		170,037	290,423
Non-controlling interest		160,474	130,561
TOTAL LIABILITIES AND EQUITY		6,266,487	5,748,121
TO THE DESIGNATION OF THE PARTY		0,200,107	5,7-10,121

CONSOLIDATED INTERIM STATEMENT OF PROFIT OR LOSS FOR THE THREE-MONTH PERIOD ENDED 1 JANUARY - MARCH 31,2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Unaudited March 31, 2022	Unaudited March 31, 2021
Profit or loss			
Revenue Cost of sales (-)	17 17	2,186,803 (1,596,037)	1,211,304 (908,256)
Gross profit		590,766	303,048
	10	•	
General administration expenses (-) Other income from operating activities	18 19	(197,746) 136,984	(84,774) 84,855
Other expenses from operating activities (-)	19	(148,026)	(57,029)
Operating profit		381,978	246,100
Income from investing activities	20	17,266	234
Expense from investing activities (-)	20	(5,754)	(2)
Operating profit before finance expenses		393,490	246,332
Finance expenses (-)	21	(183,745)	(131,606)
Net profit before tax		209,745	114,726
Tax income/(expense) from operations		(9,795)	(34,845)
Current tax expense	22	(39,343)	(12,932)
Deferred tax income/(expense)	22	29,548	(21,913)
Net profit		199,950	79,881
Non-controlling interest		29,913	14,233
Equity holders of the parent		170,037	65,648
		199,950	79,881
Basic gain/(loss) per share	23	0.82	0.32
Other comprehensive income/(expense)		(1,659)	2,250
Items that will not be reclassified			
subsequently to profit or loss		(2.074)	2.012
Remeasurement of defined benefit plans Income tax relating to items that will not be		(2,074)	2,813
reclassified subsequently		415	(563)
Total comprehensive income/(loss)		198,291	82,131
Total comprehensive income/(loss) distribution:			
Non-controlling interest		29,913	14,233
Equity holders of the parent		168,378	67,898

The accompanying notes form an integral part of these consolidated financial statements.

CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY FOR THE THREE-MONTH PERIOD ENDED 1 JANUARY - MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

Accumulated other comprehensive income or expenses that will not be reclassified subsequently to profit or

				(loss)								
	Share Share capital premium		Share Share revalu		Property revaluation reserve	Accumulated loss on remeasurement of defined benefit plans	Legal Accumulated reserves deficit			Net profit/ Attributable to (loss) for the period the Parent		Total
Balance as at January 1, 2021	208,037	556,162	37,747	(35,851)	10,260	(558,898)	64,930	282,387	66,470	348,857		
Other comprehensive loss for the period, net of tax Net profit/(loss) for the period	- -	- -	- -	2,250	- -	- -	65,648	2,250 65,648	14,233	2,250 79,881		
Total comprehensive loss for the period Transfers Dividend Distribution	- - -	- - -	- - -	2,250	- - -	(4,439) 64,930	65,648 - (64,930)	67,898 (4,439)	14,233 (694)	82,131 (5,133)		
Balance as at March 31, 2021	208,037	556,162	37,747	(33,601)	10,260	(498,407)	65,648	345,846	80,009	425,855		
Balance as at January 1, 2022	208,037	556,162	-	(43,569)	10,260	(482,677)	290,423	538,636	130,561	669,197		
Other comprehensive loss for the period, net of tax	-	-	-	(1,659)	-	-	-	(1,659)	-	(1,659)		
Net profit/(loss) for the period	-	-	-	-	-	-	170,037	170,037	29,913	199,950		
Total comprehensive loss for the period Transfers Dividend Distribution	- - -	- - -	<u>.</u> -	(1,659) - -	<u>-</u> -	290,423 (3,724)	170,037 (290,423)	168,378 - (3,724)	29,913	198,291 - (3,724		
Balance as at March 31, 2022	208,037	556,162	-	(45,228)	10,260	(195,978)	170,037	703,290	160,474	863,764		

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 (Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Unaudited January 1- March 31, 2022	Unaudited January 1 - March 31, 2021
Cash flows from operating activities		481,949	322,441
Net profit/(loss) for the period		199,950	79,881
Profit (loss) continuing operations		308,566	249,236
Adjustments related to depreciation and amortization expen	ses 10.11	108,884	72,855
Adjustments related to impairment (reversal)	305 10,11	1,239	274
Adjustments related to impairment (reversal) of receivable	es 6	1,239	274
Adjustments related to provisions	23 0	20,158	16,519
Adjustments related to (reversal) of		20,130	10,517
provision for employment benefits		19,604	8,418
Adjustments related to lawsuit (reversal) of provision for	· lawsuit	554	8,101
Adjustments related to interest (income) expense	10000	139,548	117,991
Adjustments related to interest income	19	(21,561)	(4,517)
Adjustments related to interest expense	21	161,109	122,508
Adjustments related to tax (gain) loss	22	9,795	34,845
Other adjustments related to non-cash items		40,454	6,984
Adjustments regarding to (gain) loss on sale of fix assets		(11,512)	(232)
Adjustments regarding to (gain) loss on sale of tangible asset	ets	(11,512)	(232)
Changes in working capital		12,990	16,180
Adjustments related to increase in trade receivables		(327,478)	(55,505)
Adjustments related to increase in inventories		(56,829)	4,500
Adjustments related to increase in trade payables		234,979	90,833
Adjustments related to increase in other payables from ope	rations	185,688	45,142
Adjustments related to other (increase) decrease in working		(23,370)	(68,790)
Adjustments related to increase in other payables from other		(23,370)	(68,790)
Cash generated from operations		521,506	345,297
Payments related with provision for employee benefits		(4,013)	(2,623)
Tax paid	22	(35,663)	(17,708)
Payments for other provisions	22	(33,003)	(2,541)
Other cash inflows (outflows)	6	119	16

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 (Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Unaudited January 1 - March 31, 2022	Audited January 1 - March 31, 2021
Cash flows from investing activities		(97,417)	(53,968)
Proceeds from sales of property, plant, equipment			
and intangible assets		13,423	272
Proceeds from sales of property, plant, equipment	10	13,423	272
Payment for purchase of property, plant		,	
and equipment, intangible assets		(105,158)	(43,459)
Payment for purchase of property, plant and equipment	10	(103,230)	(40,361)
Payment for purchase of intangible assets	10	(1,928)	(3,098)
Cash payments for capital expenditures	9	(27,243)	(15,298)
Interest received	19	21,561	4,517
Cash flows from financing activities		(415,074)	(64,223)
Proceeds from bank loans		_	634,489
Proceeds from borrowings			414,489
Proceeds from bonds		_	220,000
Repayment of lease liabilities		(102,019)	(75,281)
Bank borrowings paid		(168,759)	(529,306)
Cash used for repayment of borrowings		(18,759)	(441,395)
Cash used for repayment of bonds		(150,000)	(87,911)
Repayment of obligations under finance leases		(40,055)	(24,857)
Interest paid		(100,517)	(64,135)
Dividend paid		(3,724)	(5,133)
Net increase (decrease) in cash and cash equivalents		(30,542)	204,250
Cash and cash equivalents at the beginning of the period	4	680,241	374,997
Cash and cash equivalents at the end of the period	4	649,699	579,247

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 1 - ORGANIZATION AND OPERATIONS OF THE GROUP

MLP Sağlık Hizmetleri A.Ş. ("MLP Sağlık") has started its healthcare services operations in 1993, with the opening of Sultangazi Medical Center within the structure of Yükseliş Sağlık Hizmetleri Gıda Tekstil San. Ltd. Şti. in which Muharrem Usta is the majority shareholder. Following this, in 1995, it continues its operations, with the opening of Fatih Hospital under the legal entity of Saray Sağlık Hizmet Ticaret ve Sanayi A.Ş. in which Muharrem Usta was the majority shareholder. In 2005, with the establishment of MLP Sağlık, Fatih and Sultangazi Hospitals were merged under the legal entity of MLP Sağlık.

As of March 31, 2022, MLP is the holding company of 17 subsidiaries (December 31, 2021: 17) (collectively referred as the "Group"), each operating in the healthcare sector in Turkey.

The Company's head office is located in Otakçılar Caddesi No 78 3450, Eyüp, İstanbul.

The Group has an agreement with the Social Security Institution of Turkey (the "SSI") which includes service commitment in all branches disclosed in the Operations Approval Document. SSI is a state enterprise which pays the healthcare expenditures of the citizens of Turkey who are members of the social security system based on the law numbered 5510, and manages social security premiums and short and long term insurance expenses. According to the agreement, the Group is obliged to provide the healthcare services and to issue invoices to the SSI and patients in line with the Communiqué of Health Services published by the SSI. This transaction is performed through Medula, a web based software system, by assessing the right of the patient and obtaining provisions. As a result of the assessment the expenses relating to patients with no SSI, coverage is not charged to SSI. The healthcare expenses provided to the patients are invoiced based on the terms of the Communiqué of Health Services. In this Communiqué SSI determined a price list based on the treatments provided. Invoices are issued based on the price list announced by the Communiqué. SSI has the right not to pay the invoice or make a deduction if the treatments provided are not in compliance with the terms.

The Company is registered to the Capital Markets Board ("CMB") and its shares have been quoted on the Borsa İstanbul A.Ş. ("BİAŞ or "Borsa" or "BİST") since February 13, 2018. In accordance with the resolution numbered 21/655 on July 23, 2010 of CMB; according to the records of Central Registry Agency (CRA); shares representing 33.36% as of March 31 2022, of MLP Sağlık are accepted as "in circulation". As of April 1, 2022, this ratio is 33.36% (Note 16).

Approval of financial statements

Board of Directors has approved the financial statements and delegated authority for publishing it on May 10, 2022.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 1 - ORGANIZATION AND OPERATIONS OF THE GROUP (Continued)

As of March 31, 2022, the subsidiaries of the Company are:

Name Location and base of operation

Batman - İzmir - Gaziantep Sentez Sağlık Hizmetleri A.Ş. ("Sentez Hastaneleri") Temar Tokat Manyetik Rezonans Sağlık Hizmetleri ve Turizm A.S. ("Tokat Hastanesi") **Tokat** Samsun Medikal Grup Özel Sağlık Hizmetleri A.Ş. ("Samsun Hastanesi") Samsun-İstanbul Özel Samsun Medikal Tıp Merkezi ve Sağlık Hizmetleri Tic. Ltd. Şti. ("Samsun Tip Merkezi") Samsun Kuzey Medikal Pazarlama İnşaat Taşımacılık San. ve Tic. Ltd. Şti. ("Kuzey") Ankara Artımed Medikal Sanayi ve Ticaret Ltd. Şti. ("Artımed") Ankara MS Sağlık Hizmetleri Ticaret A.S. ("MS Sağlık") Ankara Mediplaza Sağlık Hizmetleri Ticaret A.Ş. ("Mediplaza") Gebze - İzmit 21. Yüzyıl Anadolu Vakfı ("21. Yüzyıl Anadolu Vakfı") İstanbul BTN Sigorta Aracılık Hizmetleri A.S. ("BTN Sigorta") İstanbul Endmed Endüstri Medikal Malzeme Cihazlar San. Tic. Ltd. Sti. ve Kuzey Medikal Pazarlama İnşaat Taşımacılık San. ve Tic. Ltd. Şti. İş Ortaklığı ("Kuzey Hastaneler Birliği" ya da "KHB") İstanbul Sotte Sağlık Temizlik Yemek Medikal Turizm Insaat San. ve Tic. A.Ş. ("Sotte Sağlık Temizlik Yemek") İstanbul - Ankara MA Group Sağlık ve Danışmanlık Hizmetleri Ticaret A.Ş. ("MA Group") İstanbul BTN Asistans Sağlık Hizmetleri A.Ş. ("BTN Asistans") İstanbul BTR Sağlık Hizmetleri A.Ş. ("BTR Sağlık") İstanbul İstanbul Meditime Sağlık Hizmetleri Ticaret Ltd. Şti. ("Meditime Sağlık") İstanbul MLP Gaziantep Sağlık Hizmetleri Anonim Şirketi ("MLP Gaziantep Sağlık") Gaziantep

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS

2.1 Basis of Presentation

Statement of Compliance with TFRS

The condensed consolidated financial statements of the Group have been prepared in accordance with the Turkish Financial Reporting Standards, ("TFRS") and interpretations as adopted in line with international standards by the Public Oversight Accounting and Auditing Standards Authority of Turkey ("POA") in line with the communiqué numbered II-14.1 "Communiqué on the Principles of Financial Reporting In Capital Markets" ("the Communiqué") announced by the Capital Markets Board of Turkey ("CMB") on June 13, 2013 which is published on Official Gazette numbered 28676.

The Company prepared its condensed interim financial statements for the period ended 31 March 2022 in accordance with ("IAS") 34 "Interim Financial Reporting". The condensed interim financial statements and its accompanying notes are presented in compliance with the format recommended by CMB including its mandatory information. In compliance with the IAS 34, entities have preference in presenting their interim financial statements whether full set or condensed. In this framework, the Company preferred to present its interim financial statements in condensed.

Interim condensed financial statements of the Group do not include all the information and disclosures required in the annual financial statements, therefore should be read in conjunction with the Company's annual financial statements as of 31 December 2021.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.1 Basis of Presentation (Continued)

Currency Used

Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency. For the purpose of the consolidated financial statements, the results and financial position of each entity consolidated are expressed in Turkish Lira ("TL"), which is the functional currency of the Company and all its subsidiaries and the presentation currency of the Group.

Inflation accounting

In accordance with the CMB's decision dated March 17, 2005 and numbered 11/367, for companies operating in Turkey and preparing financial statements in accordance with the Turkish Accounting Standards, the application of inflation accounting has been terminated as of January 1, 2005. Accordingly, as of January 1, 2005, "Financial Reporting in High Inflation Economies" Standard ("TAS 29") has not been applied.

Restatement and errors in the accounting policies and estimates

The Group's consolidated financial statements have been prepared in comparison with the previous period in order to give accurate trend analysis regarding the financial position and performance. Where necessary, comparative figures have been reclassified to conform to the presentation of the current period consolidated financial statements and significant changes are explained.

In the previous year, the Group had not reclassified certain comparative balances in order to conform to current year's presentation in the consolidated financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.1 Basis of Presentation (Continued)

Basis of Consolidation

The details of the Company's subsidiaries as at March 31, 2022 and December 31, 2021 are as follows:

Proportion of ownership and voting power held(%)					
		Place of	March 31,	December 31,	Principal
Subsidiaries in	corporatio	n and operation	2022	2021	activity
Sentez Hastaneleri	Batman	-İzmir-Gaziantep	56.00%	56.00%	Hospital services
Tokat Hastanesi		Tokat	58.84%	58.84%	Hospital services
Samsun Hastanesi		Samsun	80.00%	80.00%	Hospital services
Samsun Tıp Merkezi (1)	Samsun	100.00%	100.00%	Hospital services
MS Sağlık		Ankara	75.00%	75.00%	Hospital services
Mediplaza		Gebze-İzmit	75.00%	75.00%	Hospital services
MA Group (3)		İstanbul	51.00%	51.00%	Hospital services
BTR Sağlık Hizmetleri		İstanbul	100.00%	100.00%	Hospital services
Meditime Sağlık		İstanbul	100.00%	100.00%	Hospital services
MLP Gaziantep Sağlık		Gaziantep	60.00%	60.00%	Hospital services
Sotte Sağlık Temizlik Y	/emek	İstanbul-Ankara	100.00%	100.00%	Ancillary services
Kuzey		Ankara	100.00%	100.00%	Ancillary services
Artımed		Ankara	100.00%	100.00%	Ancillary services
21. Yüzyıl Anadolu Va	kfi (1) (2)	İstanbul	100.00%	100.00%	Ancillary services
BTN Sigorta (4)		İstanbul	100.00%	100.00%	Ancillary services
Kuzey Hastaneler Birli	ği ("KHB") İstanbul	99.90%	99.90%	Ancillary services
BTN Asistans (4)		İstanbul	100.00%	100.00%	Ancillary services

- (1) Represents voting power held.
- (2) In 2011, the Group with the help of its real person shareholders decided to establish a medical university. Based on current legislation, foundations have to be owned by real persons rather than companies and since MLP could not be the shareholder of an association, Muharrem Usta, one of the shareholders in the company, was assigned as the chairman of the board of the foundation. The purpose of the foundation is to establish a medical university in order to align one of the hospitals of the Group to that university. Although, MLP has no shareholder interest in the foundation, the financial statements of the foundation are consolidated to the financial statements in accordance with IFRS 10 as the Company achieved the control by having power and the ability to use its power on the future benefit and cost of the foundation. In addition, the Company has rights to the financial and operating policies
- (3) The Company took liquidation decision on December 25, 2017.
- (4) The Company has decided to cease all activities as of September 18, 2020 on September 15, 2020.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.1 Basis of Presentation (Continued)

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company:

- Has power over the investee,
- Is exposed, or has rights, to variable returns from its involvement with the investee and
- Has the ability to use its power to affect its returns.

The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.

In cases where the Company has no majority voting rights on the company/asset invested, it still has the control power over that company/asset if the Company alone has sufficient voting rights to manage the investment operations of that company/asset. The Company considers all events and requirements including the items listed below to evaluate if its voting power is sufficient to get control power in an investment:

- The comparison of the Company's voting right and other shareholders' voting rights;
- Potential voting rights of the Company and other shareholders;
- Rights emerging from other agreements upon contracts;
- Other events and requirements showing the potential power of the Company in managing operation decisions (including the voting held on prior period general assemblies).

Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Company gains control until the date when the Company ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income are attributed to the owners of the Company and to the non-controlling interests. Total comprehensive income of subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

Where necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with those used by other members of the Group.

All intra-group assets and liabilities, equities, income and expenses and cash flows resulting from of Group companies' transactions are eliminated on consolidation.

Changes in the Group's ownership interests in existing subsidiaries

Changes in the Group's ownership interests in subsidiaries that do not result in the Group losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the Group's interests and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to owners of the Company.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.1 Basis of Presentation (Continued)

When the Group loses control of a subsidiary, a gain or loss is recognised in profit or loss and is calculated as the difference between (i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and (ii) the previous carrying amount of the assets (including goodwill), and liabilities of the subsidiary and any non-controlling interests. All amounts previously recognised in other comprehensive income in relation to that subsidiary are accounted for as if the Group had directly disposed of the related assets or liabilities of the subsidiary (i.e. reclassified to profit or loss or transferred to another category of equity as specified/permitted by applicable IFRSs). The fair value of any investment retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under IAS 39, when applicable, the cost on initial recognition of an investment in an associate or a joint venture.

2.2 Changes in Accounting Policies

Significant changes made in accounting policies are applied retrospectively and prior year financial statements are restated. In current period, the Group has no changes in its accounting policies other than the change disclosed in Note 2.1.

2.3 Changes in the Accounting Estimates and Errors

If changes in accounting estimates are for only one period, changes are applied on the current year but if the changes in accounting estimates are for the following periods, changes are applied both on the current and the following years prospectively. In the current period, the Group has no changes in the accounting estimates and errors.

2.4 Significant Accounting Estimates and Decisions

Preparation of consolidated financial statements requires management to make estimations and assumptions which may affect the reported amounts of assets and liabilities as of the statement of financial position date, the disclosure of contingent assets and liabilities and the reported amounts of income and expenses during the financial period. The accounting assessments, estimates and assumptions are reviewed considering past experiences, other factors and reasonable expectations about future events under current conditions. Although the estimations and assumptions are based on the best estimates of the management's existing incidents and operations, they may differ from the actual results.

Effect of Covid 19 Outbreak on Group Activities

Covid-19 spread effect within the World and Turkey as well as duration can not be estimated yet clear. As the severity and duration of the effects become clearer, it will be possible to make a more specific and healthy evaluation for the medium and long term. However, while preparing the consolidated financial statements as of 31 March 2022, the possible effects of the Covid-19 outbreak were evaluated and the estimates and assumptions used in the preparation of the financial statements were reviewed. In this context, the Group has tested possible impairment in the values of financial assets, stocks, tangible and intangible fixed assets included in the consolidated financial statements as of 31 March 2022, and no impairment was detected.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

- 2.5 Amendments in International Financial Reporting Standards ("TFRS")
- (a) Standards, amendments and interpretations applicable as at 31 March 2022:
- Amendments to TFRS 7, TFRS 4 and TFRS 16 Interest Rate Benchmark Reform Phase 2 (effective 1 January 2021); The Phase 2 amendments address issues that arise from the implementation of the reforms, including the replacement of one benchmark with an alternative one. The Phase 2 amendments provide additional temporary reliefs from applying specific TAS 39 and TFRS 9 hedge accounting requirements to hedging relationships directly affected by IBOR reform.
- Amendments to TFRS 4 Insurance Contracts deferral of TFRS 9 (effective 1 January 2021); These amendments defer the date of application of TFRS 17 by two years to 1 January 2023 and change the fixed date of the temporary exemption in TFRS 4 from applying TFRS 9, Financial instrument until 1 January 2023.
- Amendment to TFRS 16, 'Leases' Covid-19 related rent concessions Extension of the practical expedient (effective 1 April 2021); As a result of the coronavirus (COVID-19) pandemic, rent concessions have been granted to lessees. In May 2020, the IASB published an amendment to TFRS 16 that provided an optional practical expedient for lessees from assessing whether a rent concession related to COVID-19 is a lease modification. On 31 March 2021, the IASB published an additional amendment to extend the date of the practical expedient from 30 June 2021 to 30 June 2022. Lessees can elect to account for such rent concessions in the same way as they would if they were not lease modifications. In many cases, this will result in accounting for the concession as variable lease payments in the period(s) in which the event or condition that triggers the reduced payment occurs.
- (b) Standards, amendments and interpretations that are issued but not effective as at 31 March 2022:
- A number of narrow-scope amendments to TFRS 3, TAS 16, TAS 37 and some annual improvements on TFRS 1, TFRS 9, TAS 41 and TFRS 16; effective from annual periods beginning on or after 1 January 2022.
 - Amendments to TFRS 3, 'Business combinations' update a reference in TFRS 3 to the Conceptual Framework for Financial Reporting without changing the accounting requirements for business combinations.
 - Amendments to TAS 16, 'Property, plant and equipment' prohibit a company from deducting from the cost of property, plant and equipment amounts received from selling items produced while the company is preparing the asset for its intended use. Instead, a company will recognise such sales proceeds and related cost in profit or loss.
 - Amendments to TAS 37, 'Provisions, contingent liabilities and contingent assets' specify which costs a company includes when assessing whether a contract will be loss-making.
 - Annual improvements make minor amendments to IFRS 1, 'First-time Adoption of TFRS', TFRS 9, 'Financial Instruments', TAS 41, 'Agriculture' and the Illustrative Examples accompanying TFRS 16, 'Leases'.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

- 2.5 Amendments in International Financial Reporting Standards ("TFRS")
- Amendments to TAS 1, Presentation of financial statements' on classification of liabilities; effective date deferred until accounting periods starting not earlier than 1 January 2024. These narrow-scope amendments to TAS 1, 'Presentation of financial statements', clarify that liabilities are classified as either current or non-current, depending on the rights that exist at the end of the reporting period. Classification is unaffected by the expectations of the entity or events after the reporting date (for example, the receipt of a waiver or a breach of covenant). The amendment also clarifies what TAS 1 means when it refers to the 'settlement' of a liability.
- Narrow scope amendments to TAS 1, Practice statement 2 and TAS 8; effective from annual periods beginning on or after 1 January 2023. The amendments aim to improve accounting policy disclosures and to help users of the financial statements to distinguish between changes in accounting estimates and changes in accounting policies.
- Amendment to TAS 12 Deferred tax related to assets and liabilities arising from a single transaction; from annual periods beginning on or after 1 January 2023. These amendments require companies to recognise deferred tax on transactions that, on initial recognition give rise to equal amounts of taxable and deductible temporary differences.
- TFRS 17, 'Insurance Contracts', as amended in December 2021; effective from annual periods beginning on or after 1 January 2023. This standard replaces TFRS 4, which currently permits a wide variety of practices in accounting for insurance contracts. TFRS 17 will fundamentally change the accounting by all entities that issue insurance contracts and investment contracts with discretionary participation features.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 3 - RELATED PARTY DISCLOSURES

Transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note.

The details of short-term receivables and payables as of 31 March 2022 are as follows:

	<u>Receiva</u> Currei			<u>Payables</u> Current		
Shareholders	Trade	Non-trade	Trade	Non-trade		
Muharrem Usta	-	71,743	-	50		
Adem Elbaşı	-	2,015	-			
	-	73,758	-	50		
Other companies controlled by the sharehold	ers					
A ve A Sağlık A.Ş. (1)	-	-	10,836	-		
Livart Tüp Bebek Özel Sağlık Hiz. A.Ş.	2,727	-	2,373	-		
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (2)	28	-	1,900	-		
Pozitif Medikal Sistemler San. ve Tic. Ltd. Şti.	1	-	509	-		
Saray Eczanesi	-	-	1,330	-		
Samsunpark Özel Sağlık Tıbbı						
Malz. İnş. Tur. Tem. Tic. A.Ş. (3)	-	-	5,267	-		
Cotyora Med. Özel Sağ. Taah. Hz.						
İnş. Tr. Loj. Ltd. Şti. (4)	-	-	2,576	-		
Mp Sağlık ve Tic. A.Ş.	-	-	2,215	733		
Tokat Emar Sağlık Hiz. Ltd. Şti.	-	-	381	-		
Mt Sağlık Ürünleri San. ve Tic. A.Ş.	-	-	209	-		
Diasan Basım ve Form Matbaacılık San. ve Tic.	A.Ş	-	7	-		
Atk Sağlık Hizmetleri Ve Danışmanlık A.Ş.	-	-	287	-		
Other	42	154	-	16		
	2,798	154	27,890	749		
	2,798	73,912	27,890	799		

⁽¹⁾ A ve A Özel Sağ. Hiz. ve Cih. Teks. San. Tic. Ltd. Şti. provides cleaning materials for the hospitals.

⁽²⁾ Fom Grup Mimarlık İnşaat ve Tic. A.Ş. provides turn key project management services for the furniture & fixture and leasehold improvements of the hospitals and audit of construction of the Group hospitals.

⁽³⁾ Samsunpark Özel Sağlık Tıbbı Malz. İnş. Tur. Tem. Tic. A.Ş. provides cleaning, catering and laundry services for the Group.

⁽⁴⁾ Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. provides cleaning and catering services for the Group.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 3 - RELATED PARTY DISCLOSURES (Continued)

_	31 December 2021					
		vables ırrent	Payables Current			
Shareholders	Trade	Non-trade	Trade	Non-trade		
Muharrem Usta	-	52,797	-	50		
Adem Elbaşı	-	1,854	-			
	-	54,651	-	50		
Other companies controlled by the shareholders						
Miniso Mağazacılık A.Ş.	96	-	-	-		
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1)	64	-	21,301	-		
Pozitif Medikal Sistemler San. ve Tic. Ltd. Şti.	2	-	509	-		
A ve A Sağlık A.Ş. (2)	-	-	3,328	-		
Konca Özel Sağlık Hizmetleri Ltd.Şti.	-	-	-	-		
Supra A.ŞSonotom Ltd Şti.	-	-	-	-		
Ledmar Ltd Şti-Mlp A.Ş. İş Ortaklığı	-	-	-	-		
Cotyora Med. Özel Sağ. Taah. Hz.						
İnş. Tr. Loj. Ltd. Şti. (4)	-	-	2,195	-		
Saray Eczanesi	-	-	593	-		
Mp Sağlık ve Tic. A.Ş.	-	=	1,998	733		
Mt Sağlık Ürünleri San. ve Tic. A.Ş.	-	-	183	-		
Samsunpark Özel Sağlık Tıbbı Malz.						
İnş. Tur. Tem. Tic. A.Ş. (3)	-	-	4,894	-		
Diasan Basım ve Form Matbaacılık San. ve Tic. A.Ş		-	7	-		
Tokat Emar Sağlık Hiz. Ltd. Şti.	-	-	533	-		
Sanport Gayrimenkul Geliştirme İnş.Ve Tic.A.Ş	-	-	54	-		
Other	32	154	-	16		
	194	154	35,595	749		
	194	54,805	35,595	799		

^(*) Non-trade receivables from Muharrem Usta is short term due date and interest charge from the current value of internal debt ratio of Group.

Advance given to related parties, prepaid expenses

	March 31, 2022	December 31, 2021
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1)	8,918	9,005
Özel Gebze Sentez Sağlık Hizmetileri ve Tic. A.Ş.	3,007	-
Sanport Gayrimenkul Geliştirme İnş. Ve Tic. A.Ş.	279	279
Gazi Medikal Sağlık Tesisleri Ve Tic. A.Ş.	3	3
Atk Sağlık Hizmetleri ve Danışmanlık A.Ş.	-	59
	12,207	9,346

⁽¹⁾ Fom Grup Mimarlık İnşaat ve Tic. A.Ş. provides turn key project management services for the furniture & fixture and leasehold improvements of the hospitals and audit of ongoing construction of the Group hospitals.

⁽²⁾ A ve A Özel Sağ. Hiz. ve Cih. Teks. San. Tic. Ltd. Şti. provides cleaning materials for the hospitals.

⁽³⁾ Samsunpark Özel Sağlık Tıbbı Malz. İnş. Tur. Tem. Tic. A.Ş. provides cleaning, catering and laundry services for the Group.

⁽⁴⁾ Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. provides cleaning and catering services for the Group.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS **AS AT MARCH 31, 2022**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 3 - RELATED PARTY DISCLOSURES (Continued)

Fixed asset advances given to related parties

•	March 31, 2022	December 31, 2021
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1)	203,056	181,359
Mp Sağlık ve Tic. A.Ş.	68,200	68,200
	271,256	249,559

Fom Grup Mimarlık İnşaat ve Tic. A.Ş. provides turn key project management services for the furniture & fixture and leasehold improvements of the hospitals and audit of ongoing construction of the Group hospitals.

Related parties (sale and leaseback transactions)	March 31, 2022	December 31, 2021
Sancak Grup Mimarlık İnşaat ve Tic. A.Ş. (within non-current prepaid expenses)	1,827	2,024
Sancak Grup Mimarlık İnşaat ve Tic. A.Ş. (within prepaid expenses)	787	787
	2,614	2,811

The balances above are resulting from sale and leaseback transactions of Efes Hospital (branch of Sentez Hospital) and Bahçelievler Hospital's land and buildings and are deferred under prepaid expenses and amortised in proportion to the lease payments over the period for which the asset is expected to be used since such losses are compensated for by future lease payments at below market price. Land of Efes Hospital was sold to Sancak Grup Mimarlık İnsaat ve Tic. A.S in 2010, resulting in a loss of TRY6,211, which was totally booked under the other current and non-current assets as of December 31, 2010 since the operational leasing agreement would become effective in 2011 and will be effective for 15 years. The building of Bahçelievler Hospital has been sold to Sancak Grup Mimarlık İnşaat ve Tic. A.Ş. in 2009, resulting in a loss of TRY5,591. The duration of leasing agreement of the building is 15 years starting from December 2009. As of March 31, 2022, the Group has incurred rent expense amounting to TRY 197 due to amortization of prepaid rent (December 31, 2021: TRY

Lease liabilities from related parties

	March 31, 2022		Decembe	er 31, 2021
	Current	Non-current	Current	Non-current
Sanport Gayrimenkul Geliştirme İnş. ve Tic. A.Ş.	87,162	56,163	59,724	59,089
Fom Grup Mimarlık İnşaat ve Tic. A.Ş.	11,204	75,367	9,718	70,516
Özel Gebze Sentez Sağlık Hizmetleri ve Tic. A.Ş.	9,496	1,827	3,407	-
Atakum Özel Sağlik Hizmetleri İnş. Turizm ve San. Tic. A.Ş.	9,331	30,465	8,764	33,021
Mp Sağlık ve Tic. A.Ş.	2,091	-	2,966	-
Tokat Medikal Grup Sağlık Turizm İnş. San. Tic. A.Ş.	1,517	-	2,354	-
Gazi Medikal Sağlık Tesisleri ve Tic. A.Ş.	1,507	-	3,654	

	122,308	163,822	90,587	162,626
Purchases from related parties		January March 31, 20		January 1- March 31, 2021
A ve A Özel Sağ. Hız. ve Cih. Teks. San. Tic. Ltd. Şti. (1) Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (2)(3)(4)		10,5 5,5		2,721 6,466
•		16,1	53	9,187

- Cleaning material purchases (1)
- (2) Hospital rent expenses
- (3) Represents the paid rent expenses of the related period, evaluated within the scope of TFRS 16.
- (4) Turnkey fixture, private cost and hospital construction, inspection and consultancy services.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 3 - RELATED PARTY DISCLOSURES (Continued)

Operating expenses (including purchase of services)

	January 1- March 31, 2022	January 1 - March 31, 2021
Sanport Gayrimenkul Geliştirme İnş. ve Tic. A.Ş. (1) (8)	32,988	27,908
Samsunpark Özel Sağ. Tıbbi Malz. İnş. Tur. Tem. Tic. A.Ş. (4)	9,236	5,615
Atakum Özel Sağlik Hiz. İnş. Turizm ve San. Tic. A.Ş. (1) (8)	4,902	3,617
Livart Tüp Bebek Özel Sağlık Hizm. A.Ş. (2)	3,978	5,599
Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. (4)	2,542	1,785
Gazi Medikal Sağlık Tesisleri ve Tic. A.Ş. (1) (8)	2,285	2,010
Mp Sağlık ve Tic. A.Ş. (1) (8)	2,281	1,913
Tokat Medikal Grup Sağlık Turizm İnş. San. Tic. A.Ş. (1) (8)	2,185	868
Saray Eczanesi (6)	692	228
Miniso Mağazacılık A.Ş. (7)	613	-
Tokat Emar Sağlık Hiz. Ltd. Şti. (2) (5)	493	407
Özdenler Sağ. Hiz. Dan. Turz. Gıd. San. Tic. Ltd. Şti. (2)	218	163
Mt Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (3)	84	58
Özel Gebze Sentez Sağlık Hizmetleri ve Tic. A.Ş. (1) (8)	-	2.130
	62,497	52,301

- (1) Hospital rent expenses
- (2) Doctor expenses
- (3) Stationary and consumable expenses
- (4) Cleaning, catering and laundry services
- (5) Medical equipment rent expenses
- (6) Drug purchase expenses
- (7) Material purchase expenses
- (8) Represents the paid rent expenses of the related period, evaluated within the scope of TFRS 16.

Sales to related parties	January 1- March 31, 2022	January 1 - March 31, 2021
A ve A Özel Sağ. Hız. ve Cih. Teks. San. Tic. Ltd. Şti. (1)	2,403	3,617
Samsunpark Özel Sağlık Hiz.İş Sağlığı ve Güvenlik.Eğitim.Müh.Tic.l	Ltd.Şti. 104	-
Adem Elbaşı	96	68
Miniso Mağazacılık A.Ş.	51	42
Tokat Medikal Grup Sağlık Turizm İnş. San. Tic. A.Ş.	41	22
Cotyora Med.Özel Sağ.Taah. Hz. İnş. Tr. Loj. Ltd. Şti.	40	22
Samsunpark Özel Sağlık Tıbbi Malz. İnş. Turizm. Tem. Tic. A.Ş.	-	60
Saray Eczanesi	-	1
	2,735	3,832
(1) Outsourcing laboratory services		
Interest income from related parties	January 1- March 31, 2022	January 1 - March 31, 2021
Muharrem Usta	2,830	2,014
	2,830	2,014

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 3 - RELATED PARTY DISCLOSURES (Continued)

Compensation of key management personnel:

Key management personnel comprise general managers, deputy general managers and chief physicians of hospitals and head office management team.

The remuneration of directors and other members of key management during the year were as follows:

	January 1- March 31, 2022	January 1 - March 31, 2021
Salaries and other short-term benefits	8,754	5,264
	8,754	5,264

NOTE 4 - CASH AND CASH EQUIVALENTS

	March 31, 2022	December 31, 2021
Cash on hand	44,238	20,114
Cash at banks	585,932	646,208
- Demand deposits	59,224	134,341
- Time deposits	526,708	511,867
Other cash equivalents (*)	19,529	13,919
	649,699	680,241

^(*) Other cash equivalents consist of credit card receivables from banks.

NOTE 5 - FINANCIAL INSTRUMENTS

Financial Liabilities

Bank Loans and Bonds

	March 31, 2022	December 31, 2021
Short-term bank borrowings	179,992	168,744
Short-term bonds issued	320,000	400,000
Current portion of long term borrowings	384,068	372,077
- Current portion of long-term bank loans	384,068	372,077
Interest expense accruals	72,608	65,386
	956,668	1,006,207
Long-term bank loans	507,596	549,594
Long-term bonds issued	-	70,000
	507,596	619,594
Total borrowings	1,464,264	1,625,801

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 5 - FINANCIAL INSTRUMENTS (Continued)

The reconciliation of the liabilities arising from financing activities as of 1 January- 31 March 2022 and 1 January- 31 December 2021 are as follows:

		Financing	Foreign exchange effect	Disposal of		March 31,
1 J	anuary 2022	cash flows	(Note 21)	subsidiary	Other (*)	2022
Bank loans	1,625,801	(161,537)	_	<u>-</u>	_	1,464,264
Finance lease obligations	230,557	(40,055)	13,840	_	_	204,342
Lease obligations	892,791	(102,019)	8,796	-	165,931	965,499
	2,749,149	(303,611)	22,636	-	165,931	2,634,105
1 J	anuary 2021	Financing cash flows	Foreign exchange effect (Note 21)	Disposal of subsidiary	Other (*)	March 31, 2021
1 J	anuary 2021	0	exchange effect	-	Other (*)	,
		cash flows	exchange effect (Note 21)	subsidiary		2021
Bank loans	1,700,431	cash flows 127,636	exchange effect (Note 21)	subsidiary -		1,818,007

^(*) Some of the lease obligations within the scope of TFRS 16 are due to the re-measurement of the reduced lease obligations and interest expenses due to the change in the lease payments realized within the period.

As of March 31, 2022 and December 31, 2021 the repayment schedule of the total borrowings as follows:

March	า 31.	. 2022

March 31				
Currency	Weighted Average Type Effective Interest Rate	Current	Non-Current	Total
TRY	%18.39	261,946	8.047	269,993
TRY	TLRef+4-TRLibor+3.50-4.00-4.50-5.80	694,722	499,549	1,194,271
		956,668	507,596	1,464,264
D	21 2021			
December	Weighted average			
Currency	9	Current	Non-Current	Total
TRY	23.10%	673,985	79,921	753,906
TRY	TLRef+4-TRLibor+3.50%-4.00%-4.50%-5.80%	332,222	539,673	871,895
		1.006.207	619,594	1,625,801

As of March 31, 2022, there are no blocked cash accounts related to the group's loans (December 31, 2021: None).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 5 - FINANCIAL INSTRUMENTS (Continued)

As at March 31, 2022 and December 31, 2021 the repayment schedule of the borrowings in TRY are as follows:

	March 31, 2022	December 31, 2021
Interest expense accruals	72,608	65,386
To be paid within 1 year (*)	884,060	940,821
To be paid between 1-2 years	397,557	376,155
To be paid between 2-3 years	73,159	169,513
To be paid between 3-4 years	36,880	73,926-
	1,464,264	1,625,801

^(*) TRY 180,000 of the loans to be paid within one year consists of revolving loans and TRY 320,000 part consists of bond payments which will be redeemed within 1 year.

Covenants:

The Company has a structured finance facility in place. A syndicate loan agreement was signed on December 31, 2015 with seven banks including Türkiye İş Bankası A.Ş., Türkiye Garanti Bankası A.Ş., Denizbank A.Ş., Denizbank A.Ş., Denizbank A.Ş., ING European Financial Services PLC and ING Bank A.Ş. The withdrawal of the syndicate loan took place in February 2016. As a guarantee for the syndicate loan used, there is a pledge over 25% of shares (that are not publicly traded) of MLP, and shares in subsidiaries owned by MLP and all fixed assets under ownership of MLP and the MLP's bank accounts. In addition to this, the loan is secured via assignment of MLP's receivables arising from various agreements including medical tourism agreements and insurance policies.

The syndicate loan includes a number of financial covenants stated below:

The Debt Service Coverage Ratio ("DSCR") cannot be below 1.1 during the term of the agreement (2016-2024). DSCR is tested every six months starting from December 31, 2016.

Net debt to EBITDA Ratio cannot be above x4.0 for the year ended December 31, 2016 and for the six months period ended June 30, 2017, x3.5 for the year ended December 31, 2017 and for the six months period ended June 30, 2018, x3.0 for the year ended December 31, 2018 and for the six months period ended June 30, 2019 and x2.5 for the remaining period of the syndicate loan.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 5 - FINANCIAL INSTRUMENTS (Continued)

Lease Obligations

The Group has the following finance lease obligations which arose mainly due to lease of medical machinery and equipment:

			Present	value of minimum
	Minimum le	ase payments	le	ase payments
Obligations under	March 31,	December 31,	March 31	December 31,
finance leases	2022	2021	2022	2021
Within one year	145,615	131,457	119,785	128,112
In the second to fifth years inclusive	97,964	145,407	84,557	102,445
	243,579	276,864	204,342	230,557
Less : Future finance charges	(39,237)	(46,307)	-	<u> </u>
Present value of finance				
lease obligations	204,342	230,557	204,342	2 230,557
Less: Amounts due to settlement within twelve months				
(shown under current liabilities)	119,785	128,112	119,785	128,112
Present value of finance				
lease obligations	84,557	102,445	84,557	102,445
Liabilities arising from lease transactions				
Districts at 15mg it on rease transactions		March	31, 2022	December 31, 2021
Within one year			182,756	139,932
More than one year			782,743	752,859
Present value of the lease liabilities			965,499	892,791

NOTE 6 - TRADE RECEIVABLES AND PAYABLES

Trade Receivables

Current trade receivables	March 31, 2022	December 31, 2021
Trade receivables	1,326,504	1,126,769
Income accruals from continuing treatments	383,756	282,399
Other trade income accruals	40,854	32,330
Notes receivables	6,616	1,667
Trade receivables from related parties (Note 3)	2,798	194
Allowance for doubtful receivables (-)	(126,425)	(125,305)
	1,634,103	1,318,054

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 6 - TRADE RECEIVABLES AND PAYABLES (Continued)

Allowance for doubtful receivables for the trade receivables is determined depending on past experiences of irrecoverable amounts.

As of March 31, 2022, trade receivables of an initial value of TRY 126,425 (December 31, 2021: TRY 125,305) were fully impaired and fully provided for. No collaterals are received in relation to these trade receivables.

Movement of allowance for doubtful receivables

	January 1 - March 31, 2022	January 1 - March 31, 2021
Balance at beginning of the period	125,305	16,696
Charge for the period Collections	1,239 (119)	274 (16)
Balance at closing of the period	126,425	16,954
Trade Payables		
Short term trade payables	March 31, 2022	December 31, 2021
Trade payables	1,337,828	1,209,258
Trade payables due to related parties (Note 3)	27,890	35,595
Trade payables due to related parties (Note 3)	410 O47	300,239
Other expense accruals	418,047	
- ·	1,127	1,245

NOTE 7 - OTHER RECEIVABLES AND PAYABLES

Other Receivables

Other current receivables	March 31, 2022	December 31, 2021
Non-trading receivables due from related parties (Note 3)	73,912	54,805
Receivables from tax office	28,760	28,330
Deposits given	8,249	22,678
Other miscellaneous receivables	16,383	11,944
	127,304	117,757
Other non-current receivables	March 31, 2022	December 31, 2021
Deposits given	4,400	3,876
·	4,400	3,876

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 7 - OTHER RECEIVABLES AND PAYABLES (Continued)

Other Payables

Other current payables	March 31, 2022	December 31, 2021
Other taxes and funds payable	45,803	31,481
Payables relating to business combinations	30,051	29,861
Non-trading payables due to related parties (Note 3)	799	799
Other miscellaneous payables	2,230	2,826
	78,883	64,967
Other non-current payables	March 31, 2022	December 31, 2021
Payables relating to business combinations	89,261	93,102
	89,261	93,102

NOTE 8 - INVENTORIES

Inventories	March 31, 2022	December 31, 2021
Medical consumables inventory	214,579	164,452
Pharmaceutical inventory	100,500	83,447
Laboratory inventory	26,024	36,586
Other inventory	1,002	791
	342,105	285,276

NOTE 9 - PREPAID EXPENSES AND DEFERRED INCOME

Prepaid Expenses

Short term prepaid expenses	March 31, 2022	December 31, 2021
Order advances (*)	225,612	229,112
Prepaid insurance expenses	17,672	23,119
Prepaid sponsorship expenses	2,005	1,164
Prepaid rent expenses	1,156	530
Other	13,841	9,483
	260,286	263,408
Long term prepaid expenses	March 31, 2022	December 31, 2021
Fined court advances since	345,757	318,514
rixed asset advances given	343,737	310,314
Fixed asset advances given Prepaid rent expenses	2,292	2,544
Prepaid rent expenses Other	*	

^(*) Advances consist of mainly the turnkeyhospital projects regarding new and renovated hospitals and the order advances given for the construction services for the hospitals under construction.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 9 - PREPAID EXPENSES AND DEFERRED INCOME (Continued)

Deferred Income

Short term accrued income	March 31, 2022	December 31, 2021
Advances received (*)	362,385	230,309
Deferred revenue	13,421	13,421
	375,806	243,730
Long term accrued income	March 31, 2022	December 31, 2021
Deferred revenue	15,718	18,374
	15,718	18,374

^(*) Advances are received from mainly local and medical tourism related patients with regards to cost of their treatments. After treatments are completed, realized remunerations are netted with advances.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 10 - PROPERTY, EQUIPMENT AND OTHER INTANGIBLE ASSETS

		achinery and		Furniture and	Leased	Leasehold	Construction in	
Cost	Buildings	equipment	Vehicles	fixture	assets	improvements	progress	Total
Opening balance as of January 1, 2022	817	881,016	1,551	444,028	436,934	723,446	80,237	2,568,029
Additions	-	40,296	-	29,946	-	22,727	10,261	103,230
Disposals	-	(1,863)	-	(695)	(421)	-	-	(2,979)
Transfers	-	39,034	-	17,996	(6,839)	-	(50,191)	_
Closing balance as of March 31, 2022	817	958,483	1,551	491,275	429,674	746,173	40,307	2,668,280
Accumulated depreciation								
Opening balance as of January 1, 2022	(111)	(599,327)	(1,586)	(274,258)	(346,256)	(331,758)	-	(1,553,296)
Charge for the period (*)	(3)	(26,750)	(18)	(10,391)	(8,164)	(14,638)	-	(59,964)
Disposals	-	1,590	-	300	35	-	-	1,925
Transfers	-	(53)	53	-	-	-	-	
Closing balance as of March 31, 2022	(114)	(624,540)	(1,551)	(284,349)	(354,385)	(346,396)	-	(1,611,335)
Carrying value as of March 31, 2022	703	333,943	-	206,926	75,289	399,777	40,307	1,056,945

^(*) Depreciation and amortization expense of 55,523 (January 1 - March 31, 2021: TRY41,022) has been charged in 'cost of service', 7,439 (January 1-March 31, 2021: TRY4,445) has been charged in 'operating expenses' for the period ended between January 1- March 31, 2022.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 10 - PROPERTY, EQUIPMENT AND OTHER INTANGIBLE ASSETS (Continued)

	M	achinery and		Furniture and	Leased	Leasehold	Construction in	
Cost	Buildings	equipment	Vehicles	fixture	assets	improvements	progress	Total
Opening balance as of January 1, 2021	817	753,417	1,546	361,807	371,073	601,052	65,220	2,154,932
Additions	-	10,492	80	8,463	-	11,300	10,026	40,361
Disposals	_	(15)	-	(53)	-	(305)	-	(373)
Transfers	-	22,253	-	10,443	(4,058)	<u> </u>	(28,638)	
Closing balance as of March 31, 2021	817	786,147	1,626	380,660	367,015	612,047	46,608	2,194,920
Accumulated depreciation								
Opening balance as of January 1, 2021	(96)	(527,196)	(1,550)	(241,003)	(322,872)	(297,970)	-	(1,390,687)
Charge for the period	(4)	(19,278)	(19)	(7,936)	(5,319)	(10,548)	-	(43,104)
Disposals	-	15	-	39	-	279	-	333
Transfers	-	-	-	-	-	_	-	
Closing balance as of March 31, 2021	(100)	(546,459)	(1,569)	(248,900)	(328,191)	(308,239)	-	(1,433,458)
Carrying value as of March 31, 2021	717	239,688	57	131,760	38,824	303,808	46,608	761,462

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 10 - PROPERTY, EQUIPMENT AND OTHER INTANGIBLE ASSETS (Continued)

Cost	Licenses	Rights	Other	Total
Opening balance as of January 1, 2022	596,072	117,180	3,245	716,497
Additions Disposals Transfers	- - -	1,928 (857)	- - -	1,928 (857)
Closing balance as of March 31, 2022	596,072	118,251	3,245	717,568
Accumulated amortization				
Opening balance as of January 1, 2022	-	(52,272)	(1,147)	(53,419)
Charge for the period	-	(2,941)	(57)	(2,998)
Closing balance as of March 31, 2022	-	(55,213)	(1,204)	(56,417)
Carrying value as of March 31, 2022	596,072	63,038	2,041	661,151
Cost	Licenses	Rights	Other	Total
Opening balance as of January 1, 2021	596,072	82,384	3,245	681,701
Additions Transfers	- -	3,098	-	3,098
Closing balance as of March 31, 2021	596,072	85,482	3,245	684,799
Accumulated amortization				
Opening balance as of January 1, 2021	-	(42,629)	(884)	(43,513)
Charge for the period	-	(2,293)	(70)	(2,363)
Closing balance as of March 31, 2021	-	(44,922)	(954)	(45,876)
Carrying value as of March 31, 2021	596,072	40,560	2,291	638,923

NOTE 11- RIGHT OF USED ASSETS

	Hospital Buildings	Total
Opening balance as of January 1, 2022	539,308	539,308
Additions Charge for the year (*)	112,561 (45,922)	112,561 (45,922)
Closing balance as of March 31, 2022	605,947	605,947

^(*) For the period ended March 31, 2022, right of use assets depreciation expenses of 45,172 has been charged to 'cost of service' (1 January – 31 March 2021: TRY 26,962), 750 to 'general administrative and marketing expenses (1 January – 31 March 2021: TRY 426).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 (Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise	e stated.)	
NOTE 11 - RIGHT OF USE ASSETS (Continued)		
	Hospital Buildings	Total
Opening balance as of January 1, 2021	257,440	257,440
Additions Charge for the year (*)	65,549 (27,388)	65,549 (27,388
Closing balance as of March 31, 2021	295,601	295,601
NOTE 12- PAYABLES FOR EMPLOYEE BENEFITS		
Payables for employment benefits:		
	March 31, 2022	December 31, 2021
Fees payable to doctors and other personnel Social security premiums payable	105,217 27,348	79,800 20,617
	132,565	100,417
Short term provision for employment benefits:		
Short term provision for employment benefits.	March 31, 2022	December 31, 2021
Unused vacation provision	32,497	23,779
	32,497	23,779
Long term provision for employment benefits:	M1 21 2022	D
	March 31, 2022	December 31, 2021
Retirement pay provision Unused vacation provision	28,879 18,012	24,830 13,114
Chased vacation provision	46,891	37,944
NOTE 13 - OTHER ASSETS AND LIABILITIES	70,071	31,944
Other current assets:	March 31, 2022	December 31, 2021
VAT carried forward	80,969	70,853
Other miscellaneous current assets	7,848	5,744
	88,817	76,597
NOTE 14 - PROVISIONS		
Other short-term provisions:	March 31, 2022	December 31, 2021
Litigation provisions Social Security discounts provisions	26,069 17,558	25,515 3,513
	43,627	29,028

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 15 - COMMITMENTS

March 31, 2022	Total	TRY	USD	EUR
A, CPM given on behalf of its own legal entity	154,329	152,044	156	_
-Collateral	154,329	152,044	156	_
-Pledge	-	-	-	-
-Mortgage	-	-	-	-
B , CPM given on behalf of the subsidiaries included	in			
full consolidation (*)	59,237	59,237	_	_
-Collateral	59,237	59,237	-	-
-Pledge	-	-	-	-
-Mortgage	-	-	-	-
C, CPM given for execution of ordinary				
commercial activities to collect third parties debt	-	-	-	-
-Collateral	-	-	-	-
-Pledge	-	-	-	-
-Mortgage	-	-	-	-
D, Total amount of other CPM giveni, Total Amount of CPM on behalf of the				
main partner	-	-	-	-
-Collateral	-	-	-	-
-Pledge	-	-	-	-
-Mortgage	-	-	-	-
ii, Total amount of CPM given on behalf of other				
Company companies that do not cover B and	C -	-	_	_
-Collateral	-	-	-	-
-Pledge	-	-	-	-
-Mortgage	-	-	-	-
iii, Total amount of CPM on behalf of third parties t do not cover C,	hat -	-	_	_
-Collateral	-	-	-	-
-Pledge	-	-	-	-
-Mortgage	-	-	-	
TOTAL	213,566	211,281	156	

^(*) The Group has given guarantees amounting to TRY 150,306 related to the loans in Note 5 for the companies under full consolidation.

Guarantees given generally include letters of guarantee received from banks to be given to institutions and suppliers in order to participate in government tenders.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 15 - COMMITMENTS (Continued)

31 December 2021	Total TRY Equivalent	TRY	USD	EUR
A.CPM given on behalf of its own legal entity	137,079	135,055	156	-
- Collateral	137,079	135,055	156	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
B. CPM given on behalf of the subsidiaries				
included in full consolidation (*)	43,988	43,988	-	-
- Collateral	43,988	43,988	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
C. CPM given for execution of ordinary				
commercial activities to collect third parties debt	_	-	-	_
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
D. Total amount of other CPM given				
i. Total Amount of CPM on behalf of the main partner	-	-	-	-
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
ii. Total amount of CPM given on behalf of other				
Company companies that do not cover B and C	_	-	-	_
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
iii. Total amount of CPM on behalf of third				
parties that do not cover C	_	-	-	_
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	
Total	181,067	179,043	156	-

^(*) The Group has given guarantees amounting to TRY81,807 related to the loans in Note 5 for the companies under full consolidation.

Guarantees given generally include letters of guarantee received from banks to be given to institutions and suppliers in order to participate in government tenders.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 16 - SHARE CAPITAL/OTHER RESERVES

		March 31,		December 31,
Shareholders	(%)	2022	(%)	2021
Lightyear Healthcare B.V. (*)	34.67	72,131	30.69	63,844
Sancak İnşaat Turizm Nakliyat ve Dış Ticaret A.Ş.	15.35	31,943	15.35	31,943
Muharrem Usta	8.98	18,678	8.98	18,678
Adem Elbaşı	2.99	6,226	2.99	6,226
İzzet Usta	1.20	2,490	1.20	2,490
Saliha Usta	0.90	1,868	0.90	1,868
Nurgül Dürüstkan Elbaşı	0.90	1,868	0.90	1,868
Hujori Financieringen B.V. (*)	-	-	3.98	8,287
Publicly Traded (**)	35.01	72,833	35.01	72,833
Nominal capital	100.00	208,037	100.00	208,037

- (*) Turk Ventures Adv. Ltd. provides consultancy services to Dutch shareholders TPEF (Hujori Financieringen B.V. ("Hujori") and Lightyear Healthcare B.V. ("Lightyear")) in its Istanbul liaison office. Consulted Hujori and Lightyear have merged under Lightyear. With this merger, 8,287 thousand shares corresponding to 3.98% of the non-public portion owned by Hujori, and 418 thousand shares corresponding to 0.57% of the publicly traded portion, were transferred to Lightyear.
- (**) The shareholders of the Company purchased 6,827 thousand shares from the publicy traded portion of the capital. Distribution of the shares purchased is as follows; 3,224 thousand shares representing 4.43% of the publicly traded portion were purchased by Lightyear, 1,613 thousand shares representing 2.21% of the publicly traded portion of the capital were purchased by Sancak İnşaat, 943 thousand shares representing 1.29% of the publicly traded portion of the capital were purchased by Muharrem Usta, 418 thousand shares representing 0.57% of the publicly traded portion of the capital were purchased by Hujori, 314 thousand shares representing 0.43% of the publicly traded portion of the capital were purchased by Adem Elbaşı and lastly other shareholders purchased 314 shares representing 0.43% of the publicly traded portion. 1,613 thousand shares purchased by Sancak İnşaat from the publicy traded portion were sold on September 24, 2018. 126 thousand shares purchased by İzzet Usta and 18 thousand shares purchased by Adem Elbaşı from the publicly traded portion were sold.

As of March 31, 2022 the total number of ordinary shares is 208,037 thousand shares (2021: 208,037 thousand shares) with a par value of TRY1 per share (2021: TRY1 per share).

The share capital is divided into 208,037 thousand shares (December 31, 2021: 208,037 thousand shares), with 88,229 thousand A type shares and 119,808 thousand B type shares.

In accordance with the Capital Markets Board's (the "CMB") Resolution No: 21/655 issued on July 23, 2010, it is regarded that 33.36% of the shares are in circulation in accordance with CSD as of March 31, 2022 (Note 1). Shares in circulation rate is 33.36% as of April 1, 2022.

Share premiums:

	March 31, 2022	December 31, 2021
Share Premiums	556,162	556,162
	556,162	556,162

On February 7, 2018, the Group launched initial public offering ("IPO") of 72,834 thousand B type bearer shares corresponding to 35.01% of total shares. From the initial public offering, TRY600,000 was generated to the Group. After the IPO related expenses amounting to TRY12,259 were deducted from proceeds, out of TRY587,741, share capital increase was made with the amount of TRY31,579 and the remaning amount was used in the share premium increase by TRY556,162.

Reserves:

	March 31, 2022	December 31, 2021
Legal reserves	302	302
Restricted reserves appropriated from profit	9,958	9,958
	10,260	10,260

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 16- SHARE CAPITAL/OTHER RESERVES (Continued)

Legal reserves

The legal reserves consist of first and second legal reserves, appropriated in accordance with the Turkish Commercial Code. The first legal reserve is appropriated out of historical statutory profits at the rate of 5% per annum, until the total reserve reaches 20% of the historical paid-in share capital. The second legal reserve is appropriated after the first legal reserve and dividends, at the rate of 10% per annum of all cash dividend distributions.

NOTE 17 - REVENUE AND COST OF SERVICES

Revenue	January 1 - March 31, 2022	January 1 - March 31, 2021
Hospital services (*)	2,186,803	1,211,304
	2,186,803	1,211,304

(*) Hospital services includes foreign medical revenue and other income.

Cost of services	January 1 - March 31, 2022	January 1 - March 31, 2021
Doctor expenses	(464,717)	(262,670)
Material consumption	(404,717)	(241,393)
Personnel expenses	(296,463)	(160,549)
Services rendered by third parties	(152,678)	(100,317)
Depreciation and amortization expenses (Note 10,11)	(100,695)	(67,984)
Rent expenses (Hospitals)	(16,453)	(8,930)
Other (*)	(158,996)	(66,413)
	(1,596,037)	(908,256)

^(*) Other expenses mainly comprise expenses incurred for electricity, water and natural gas.

NOTE 18 - OPERATING EXPENSES

General administrative and marketing expenses	January 1- March 31, 2022	January 1 - March 31, 2021
	(01.05.1)	
Personnel expenses	(81,824)	(35,539)
Sponsorship and advertising expenses (*)	(73,120)	(25,454)
Outsourcing expenses	(16,048)	(3,258)
Depreciation and amortization expenses (Note 10,11)	(6,879)	(4,871)
Communication expenses	(3,884)	(1,600)
Rent Expenses	(2,974)	(2,102)
Maintenance and repair expenses	(1,576)	(785)
Representation and entertainment expenses	(1,247)	(937)
Bad debt allowance	(1,239)	(274)
Taxes and duties	(985)	(761)
Utility expenses	(779)	(266)
Other	(7,191)	(8,927)
	(197,746)	(84,774)

^(*) Sponsorship and advertising expenses includes marketing expenses related to the income of domestic and foreing medical tourism.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 19 - OTHER INCOME AND EXPENSES FROM OPERATING ACTIVITIES

Other income from operating activities	January 1- March 31, 2022	January 1 - March 31, 2021
Foreign exchange gains from operations	105,871	73,552
Interest income	21,561	4,517
Trade payables discount	322	2,236
Collection of doubtful receivables (Note 6)	119	16
Other income	9,111	4,534
	136,984	84,855
Other expenses from operating activities	January 1- March 31, 2022	January 1 - March 31, 2021
Foreign exchange losses from operations	(75,547)	(40,664)
SSI return expenses	(23,504)	(2,414)
Biomedical equipment damage	(9,084)	(2,973)
Non-operational hospital expenses	(4,867)	(1,450)
Trade receivables discount	(3,898)	(783)
Depreciation and amortization expenses (Note 10,11)	(1,310)	· · · · · -
Other expenses	(29,816)	(8,745)
	(148,026)	(57,029)

NOTE 20 - INCOME AND EXPENSES FROM INVESTING ACTIVITIES

Income from investing activities	January 1 - March 31, 2022	January 1 - March 31, 2021
Gain on sale of fixed assets	17,266	234
	17,266	234
Expense from investing activities	January 1 - March 31, 2022	January 1 - March 31, 2021
Loss on sale of fixed assets	(5,754)	(2)
	(5,754)	(2)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 (Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

(Amounts expressed in mousands Turkish Lina (TKT) unless onerwise stated	**)	
NOTE 21 - FINANCE EXPENSES		
T' ()	January 1-	January 1 -
Finance expenses (-)	March 31, 2022	March 31, 2021
Interest expenses from lease liabilities	(53,370)	(35,920)
Interest expenses from bank borrowings	(50,943)	(41,603)
Interest expenses from bonds issued	(27,160)	(25,920)
Bank commissions	(12,674)	(6,372)
Interest expenses from financial lease obligations	(5,349)	(3,309)
Other interest expenses	(11,613)	(9,384)
Total interest expenses	(161,109)	(122,508)
Net ferries and area less	(12.940)	(2.050)
Net foreign exchange loss Fair value differences of derivative financial instruments (Note 5)	(13,840) (8,796)	(3,059) (6,039)
1 air value differences of derivative financial instruments (type 3)	(0,770)	(0,037)
	(183,745)	(131,606)
NOTE 22 - TAXES ON INCOME (DEFERRED TAX ASSET AN		•
NOTE 22 - TAXES ON INCOME (DEFERRED TAX ASSET AS	ND LIABILITIES IN March 31, 2022	(CLUDED) December 31, 2021
·		·
Short term payables due to current tax	March 31, 2022	December 31, 2021
Short term payables due to current tax	March 31, 2022 39,343	December 31, 2021 35,663
Short term payables due to current tax Current period tax liabilities Current tax liabilities	March 31, 2022 39,343 39,343 March 31, 2022	December 31, 2021 35,663 35,663 December 31, 2021
Short term payables due to current tax Current period tax liabilities	March 31, 2022 39,343 39,343	December 31, 2021 35,663 35,663 December 31, 2021 82,329
Short term payables due to current tax Current period tax liabilities Current tax liabilities Current corporate tax provision	March 31, 2022 39,343 39,343 March 31, 2022	December 31, 2021 35,663 35,663 December 31, 2021 82,329
Short term payables due to current tax Current period tax liabilities Current tax liabilities Current corporate tax provision	March 31, 2022 39,343 39,343 March 31, 2022 39,343 39,343 January 1-	35,663 35,663 December 31, 2021 82,329 (46,666) 35,663 January 1 -
Short term payables due to current tax Current period tax liabilities Current tax liabilities Current corporate tax provision	March 31, 2022 39,343 39,343 March 31, 2022 39,343 39,343	December 31, 2021 35,663 35,663 December 31, 2021 82,329 (46,666) 35,663
Short term payables due to current tax Current period tax liabilities Current tax liabilities Current corporate tax provision Less: Prepaid taxes and funds Tax (expense)/income	March 31, 2022 39,343 39,343 March 31, 2022 39,343 39,343 January 1- March 31, 2022	35,663 35,663 December 31, 2021 82,329 (46,666) 35,663 January 1 - March 31, 2021
Short term payables due to current tax Current period tax liabilities Current tax liabilities Current corporate tax provision Less: Prepaid taxes and funds	March 31, 2022 39,343 39,343 March 31, 2022 39,343 39,343 January 1-	December 31, 2021 35,663 35,663 December 31, 2021 82,329 (46,666) 35,663 January 1 -

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 22 - TAXES ON INCOME (DEFERRED TAX ASSET AND LIABILITIES INCLUDED) (Continued)

Corporate Tax

The Group is subject to Turkish corporate taxes in force. The necessary provisions are allocated in the consolidated financial statements for the estimated liabilities based on the Group's results for the year. Turkish tax legislation does not permit a parent company and its subsidiary to file a consolidated tax return. Therefore, provisions for taxes, as reflected in the consolidated financial statements, have been calculated on a separate-entity basis.

Corporate tax is applied on taxable corporate income, which is calculated from the statutory accounting profit by adding non-deductible expenses, and by deducting dividends received from resident companies, other exempt income and investment incentives utilized.

The advance corporate income tax rate is 23% in 2022 (2021 25%).

In Turkey, provisional tax is calculated and accrued on a quarterly basis. The provisional tax rate to be calculated on corporate earnings during the taxation phase of 2021 corporate earnings as of temporary tax periods is 23% (2021: 25%). Losses can be carried forward for a maximum of 5 years, to be deducted from the taxable profits that will arise in future years. However, the losses incurred cannot be deducted retrospectively from the profits of previous years.

In Turkey, advance tax returns are filed on a quarterly basis in the Official Gazette dated April 22, 2021 and numbered 31462, the corporate tax rate applied in Turkey is 25% for 2021 corporate earnings, 23% for 2022, and 20% for 2023 and the following years. In Turkey, there is no procedure for a final and definitive agreement on tax assessments. Companies file their tax returns between 1 - 25 April following the close of the accounting year to which they relate. Tax authorities may, however, examine such returns and the underlying accounting records and may revise assessments within five years.

The law on amending the Tax Procedure Law and the Corporate Tax Law was enacted on 20 January 2022. It has been enacted with the number 7352 and it has been decided that the financial statements will not be subject to inflation adjustment in the 2021 and 2022 accounting periods, including the temporary accounting periods and in the provisional tax periods of the 2023 accounting period regardless of whether the conditions for the inflation adjustment within the scope of the repeated Article 298 are met. POA made a declaration on the Implementation of Financial Reporting in High Inflation Economies under TFRS on 20 January 2022 and it was stated that there was no need to make any adjustments within the scope of TAS 29 Financial Reporting in Hyperinflationary Economies in the consolidated financial statements for 2021.

Deferred Tax

The Group recognizes deferred tax assets and liabilities based upon temporary differences arising between its financial statements as reported for TFRS purposes and its statutory tax financial statements. These differences usually result in the recognition of revenue and expenses in different reporting periods for TFRS and tax purposes and they are given below. As of 31 March 2022, tax rate used in the calculation of deferred tax assets and liabilities was %20 over temporary timing differences (31 December 2021: 23% for the part that will create tax effect in 2022, 20% for the part that will generate tax in 2023 and beyond). In Turkey, the companies cannot declare a consolidated tax return, therefore subsidiaries that have deferred tax assets position were not netted off against subsidiaries that have deferred tax liabilities position and disclosed separately.

The Group revalued its tangible and intangible assets and their depreciation as of 31 December 2021, within the scope of the Tax Procedure Law General Communique (Sequence No: 530) published by the Ministry of Treasury and Finance. Due to TFRS, related assets are continued to be accounted under cost method. It has calculated the deferred tax asset/liability, which is currently calculated over the temporary difference between TFRS and TPL, over the current TPL values that will occur with the effect of revaluation, and the deferred tax income that will arise due to this application, to the extent that the recovery of the said tax advantage is deemed possible, is calculated as a single income tax accounted for in the table, the effect of deferred tax assets is TRY 59.971 thousand (31 December 2021: TRY 59.971 thousand).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 22 - TAXES ON INCOME (DEFERRED TAX ASSET AND LIABILITIES INCLUDED) (Continued)

Investment Incentive Certificate

The Group has various investment incentive certificates that were signed by the Turkish Ministry of Economy and approved by General Directorate of Incentive Implementation and Foreign Capital. With those incentives, the Group is eligible for a corporate tax deduction rate ranging between 40%- 80% for an unlimited time, which amounts to a total deferred tax asset of TRY228.549 (December 31, 2021: TRY200.394). Respective deferred tax asset was calculated to be 15%- 40% of total investment contribution with regards to the respective investment incentive certificates. Additionally, the Group is entitled to social security premium support from the Turkish Ministry of Economy, related to the hospitals that have completed their greenfield investments. Such investment income of TRY3,546 will be netted off against personnel expenses over the period of 2020-2026.

As of March 31, 2022, the Group has tax loss amounting to TRY 62,841 (December 31, 2021: TRY 95,280). TRY 14,453 (December 31, 2021: TRY 23,820) deferred tax assets have been recorded concerning this loss.

Deferred tax assets/(liabilities):	March 31, 2022	December 31, 2021
	14.450	22.020
Tax losses carried forward	14,453	23,820
Depreciation differences of tangible and intangible assets	(120,414)	(120,465)
Provision for employment termination benefits	5,776	4,966
Vacation pay liability	10,102	7,379
Temporary difference between the tax base and	(2.704)	(2.74)
carrying amount of financial liabilities	(2,581)	(3,544)
Prepaid building expenses	(396)	(707)
Tax advantage from investment incentive	228,549	200,394
Right of use asset	71,911	70,697
Other	108,025	102,922
	317,270	285,462
Deferred tax asset	444,560	421,896
Deferred tax liability	(129,135)	(136,434)
	315,425	285,462
T. 1		
Tax losses carried forward and their expiry dates are as follows:	March 31, 2022	
	Losses carried	Losses carried
	forward for	forward for
	which deferred	which deferred tax
Expiration schedule of carryforward tax losses	tax assets recognized	assets not recognized
Displacion schoule of curry for ward tax rosses	tan assets recognized	ussets not recognized
Expiring in 2022	13,192	-
Expiring in 2023	11,709	_
Expiring in 2024	6,640	=
Expiring in 2025	20,915	-
Expiring in 2026	9,320	-
Expiring in 2027	1,066	-
	62,842	-

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 22 - TAXES ON INCOME (DEFERRED TAX ASSET AND LIABILITIES INCLUDED) (Continued)

	31 December 2021	
	Losses carried forward for which deferred tax	Losses caried forward for which deferred tax
Expiration schedule of carryforward tax losses	assets recognized	assets not recognized
Expiring in 2022	29,817	-
Expiring in 2023	12,640	-
Expiring in 2024	15,924	-
Expiring in 2025	27,697	-
Expiring in 2026	9,202	<u> </u>
	95,280	-

Movement of deferred tax (assets)/liabilities for the period ended March 31, 2022 and March 31, 2021 are as follows:

Movement of deferred tax liabilities:	January 1 - March 31, 2022	January 1 - March 31, 2021	
Opening balance as at January 1	(285,462)	(217,879)	
Charged to profit or loss	(29,548)	21,913	
Charged to equity	(415)	563	
Closing balance as at year end	(315,425)	(195,403)	

The reconciliation of the current tax expense and net income for the period is as follows:

Reconcilation of tax provision:	January 1 - March 31, 2022	January 1 - March 31, 2021
Loss before tax	209,745	114,726
Tax at the domestic income tax rate of 23% (2021: 25%)	(48,241)	(22,945)
Tax effects of:		
- Expenses that are not deductible in	(21,939)	(6,074)
- Effect of tax advantage from investment incentive	28,155	12,685
- Tax losses carried forward not subject to deferred tax	· -	(22,151)
- Change in income tax rate from 20% to 25%	(9,634)	·
- Reduced corporate tax effect	24,004	3,315
- Other	17,860	325
Income tax income recognised in profit or loss	(9,795)	(34,845)

In the Material Event Disclosure dated March 26, 2021, as a result of the procedural tax review regarding the technical transactions, including the mergers of the companies in the past, 91,441 thousand TRY has been requested to be canceled and the judicial process regarding the issue continues. According to the opinion of the Company Management; Regarding the other transactions, the continuation of the legal process and the finalization accordingly, the possibility of the exit of the economic benefit resources, the opinions of the company legal consultants and tax experts, 31 March 2022 in some summary period, no provision in the financial statements in the interim financial statements. No provision has been made.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 (Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 23 - EARNINGS PER SHARE

The weighted average number of shares and earnings per share is as follows:

Earnings/(loss) per share	March 31, 2022	March 31, 2021
Weighted average number of shares	208,037	208,037
Net loss for the period for the equity holders of the parent	170,037	65,648
Earnings per share	0.82	0.32

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 24 - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

Financial Risk Factors

Foreign currency risk management

Foreign currency risk

Transactions in foreign currencies expose the Company to foreign currency risk. Exchange rate exposures are managed within approved policy parameters utilising forward foreign exchange contracts. The carrying amounts of the Group's foreign currency denominated monetary assets and monetary liabilities at the reporting date are as follows:

March 31, 2022

	TRY Equivalent (Functional currency)	USD	EUR	GBP
1. Trade receivables	67,441	3,691	823	(2)
2a. Monetary financial assets	110,355	4,097	3,078	8
2b. Non monetary financial assets	28,972	61	1,717	4
3. Other	8,312	-	510	-
4. Current Assets	215,080	7,849	6,128	10
6b. Non monetary financial assets	45,871	3,132	-	-
7. Other	235	-	14	-
8. Non-current assets	46,106	3,132	14	-
9. Total assets	261,186	10,981	6,142	10
10. Trade payables	(10,356)	(549)	(142)	-
11a. Financial liabilities (loans)	-	-	=	-
11b. Financial liabilities (leasing)	(87,845)	(535)	(4,906)	-
11c. Lease Liabilities	(11,204)	-	(687)	-
12a. Other monetary liabilities	(137,419)	(4,777)	(4,128)	(7)
13. Current liabilities	(246,824)	(5,861)	(9,863)	(7)
15a. Financial liabilities (loans)	-	-	-	-
15b. Financial liabilities (leasing)	(30,213)	(279)	(1,602)	-
15c. Lease Liabilities	(75,362)	-	(4,621)	-
17. Non-current liabilities	(105,575)	(279)	(6,223)	-
18. Total liabilities	(352,399)	(6,140)	(16,086)	(7)
19. Net assets / liability position of				
off-balance sheet derivatives (19a-19b	-	-	-	-
19a. Off balance sheet foreign currency				
derivative assets	-	-	-	-
19b. Off balance sheet foreign currency				
derivative liabilities	-	-	-	-
20. Net foreign currency asset				
liability position (9+18+19)	(91,213)	4,841	(9,944)	3
21. Monetary Items Net Foreign	` , ,	,	. , ,	
Currency Asset/Liability Position				
(1+2a+10+11+12a+14+15+16a)	(174,603)	1,648	(12,185)	(1)

As a result of the evaluation of the provision of the temporary 14th article of the Law on the Amendment of the Tax Procedure Law and the Corporate Tax Law published in the Official Gazette dated 29.01.2022 and numbered 31734; On February 15, 2022, a Currency Protected Deposit transaction amounting to TRY 102,757 (EUR 6,600) was made. Since the related EUR balance is converted to TRY on the transaction date, it is not included in the above mentioned Foreign Currency Position.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 24 - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Continued)

December 31, 2021

	TRY Equivalent			
	(Functional			
	currency)	USD	EUR	GBP
1. Trade receivables	44,218	2,454	845	(2)
2a. Monetary financial assets	325,178	10,577	12,794	(2)
2b. Non monetary financial assets	25,892	28	1,734	4
3. Other	7,134	20	486	4
4. Current Assets	402,422	13,059	15,859	6
6b. Non monetary financial assets	40,646	3,132	13,637	-
7. Other	31	5,152	2	_
8. Non-current assets	40,677	3,132	$\frac{2}{2}$	_
9. Total assets	443,099	16,191	15,861	6
10. Trade payables	(15,333)	(867)	(278)	-
11a. Financial liabilities (loans)	(15,555)	(007)	(270)	_
11b. Financial liabilities (leasing)	(99,753)	(731)	(6,148)	_
11c. Lease Liabilities	(9,720)	(731)	(662)	_
12a. Other monetary liabilities	(156,011)	(5,448)	(5,808)	(2)
13. Current liabilities	(280,817)	(7,046)	(12,896)	(2)
15a. Financial liabilities (loans)	-	-	-	-
15b. Financial liabilities (leasing)	(37,963)	(279)	(2,339)	_
15c. Lease Liabilities	(70,519)	-	(4,803)	_
17. Non-current liabilities	(108,482)	(279)	(7,142)	_
18. Total liabilities	(389,299)	(7,325)	(20,038)	(2)
19. Net assets / liability position of				
off-balance sheet derivatives (19a-19b)	-	-	-	-
19a. Off balance sheet foreign currency				
derivative assets	-	-	-	-
19b. Off balance sheet foreign currency				
derivative liabilities	-	-	-	-
20. Net foreign currency asset				
liability position (9+18+19)	53,800	8,866	(4,177)	4
21. Monetary Items Net Foreign				
Currency Asset/Liability Position				
(1+2a+10+11+12a+14+15+16a)	(19,903)	5,706	(6,399)	-

Foreign currency sensitivity

The Group is exposed to foreign exchange risk arising primarily from USD and EUR.

The following table details the Group's sensitivity to a 20% increase and decrease against the relevant foreign currencies. 20% is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management's assessment of the possible change in foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the period end for a 20% change in foreign currency rates. The sensitivity analysis includes external loans as well as loans to foreign operations within the Group where the denomination of the loan is in a currency other than the currency of the lender or the borrower. A positive number below indicates an increase in profit/loss or equity where the TRY strengthens 20% against the relevant currency. For a 20% weakening of the TRY against the relevant currency, there would be a comparable impact on the profit before tax or equity, and the balances would be negative.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 (Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 24 - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Continued)

March 31, 2021	Profit/Loss	
In the case of US dollar gaining 20% value against TRY	Valuation of foreign currency	Devaluation o foreign currency
1 - USD net asset/(liability) 2- Po,tion hedged against USD ,isk (-)	14,180	(14,180)
3- USD net effect (1 +2)	14,180	(14,180)
In the case of EUR gaining 20% value against TRY		
4 - EUR net asset/(liability) 5 - Portion hedged against EUR risk (-)	(32,434)	32,434
6- EUR net effect (4+5)	(32,434)	32,434
TOTAL (3 + 6)	(18,254)	18,254
31 December 2021 In the case of US dollar gaining 20% value against TRY	Valuation of foreign currency	Devaluation of foreign currency
1 - USD net asset/liability 2- Portion hedged against USD risk (-)	23,009	(23,009)
3- USD net effect (1 +2)	23,009	(23,009)
In the case of EUR gaining 20% value against TRY		
4 - EUR net asset/liability 5 - Portion hedged against EUR risk (-)	(12,265)	12,265
6- EUR net effect (4+5)	(12,265)	12,265
Total (3+6)	10,744	(10,744)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 25 - EVENTS AFTER THE REPORTING PERIOD

MLP Health Services Inc. ("Company") and MP Sağlık Hizmetleri A.Ş ("MP Sağlık") have signed a share transfer agreement dated 16 March 2022 regarding the share transfers of its two subsidiaries. According to this share transfer agreement, the company will transfer its 56% shares in Sentez Sağlık Hizmetleri A.Ş ("Sentez"), one of its subsidiaries, to MP Sağlık, which is a 44% minority shareholder. The Company will increase its shareholding rate from 75% to 100% by purchasing the 25% shares of MP Sağlık, the minority partner of MS Sağlık Hizmetleri Ticaret A.Ş ("MS Sağlık"), one of its subsidiaries.

The aforementioned share transfer agreement is a conditional/forward agreement, and if the Competition Board's permission is obtained and certain commercial conditions are fulfilled, the share transfers will be made mutually.

In the event that the closing procedures are carried out pursuant to the share transfer agreement, all shares of our Company in Sentez Sağlık will be transferred to the buyer MP Sağlık, and our shareholding rate in MS Health will be increased from 75% to 100%, making our Company the sole shareholder.

Three hospitals (İzmir, Gaziantep and Batman) are operated under the subsidiary of Sentez. Liv Hospital Ankara hospital is operated under MS Health, the other subsidiary subject to the transfer.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

APPENDIX I EARNINGS BEFORE INTEREST TAXES DEPRECIATION AND AMORTISATION ("EBITDA")

Interest, Tax, Depreciation and Amortization ("EBITDA") is calculated by the Group Management with the addition of the period's depreciation and amortization, financial income and expenses, other adjustments and tax deductions to net loss before tax.

The EBITDA calculation movements for the period ended March 31, 2022 and March 31, 2021 are as follow:

EBITDA CALCULATION	March 31, 2022	March 31, 2021
i. Net loss before tax	209,745	114,726
ii. Depreciation and amortization of tangible and intangible	207,743	114,720
fixed assets including non-cash provisions related to assets		
such as goodwill	108,884	72,855
iii. Total net finance expenses, net of interest income	139,548	117,991
iv. Fx gains/losses, net under finance expenses	22,636	9,098
v. Fair value differences of derivative instruments (Note 21)	22,030	7,070
vi. Extraordinary (income)/expenses	24,410	18,503
vii. Rediscount income/expense (net imputed interest)	3,576	(1,453)
viii. Gain on bargain purchase price	3,370	(1,433)
viii. Legal case provision expenditures which are reflected to	-	-
financial statements by the general accounting principles;	554	5,560
xi. Unused vacation pay provision expenses which are reflected to	334	3,300
	12 616	4.401
financial statements by the general accounting principles;	13,616	4,491
x. Retirement pay provision expenses which are reflected to	5 000	2.027
financial statements by the general accounting principles;	5,988	3,927
xi. Doubtful receivables provision expenses which are reflected to	1 120	250
financial statements by the general accounting principles;	1,120	258
xii. Non cash sale and lease back expenses which are reflected to	105	405
financial statements by the general accounting principles (Note 3);	197	197
xiii. (Income)/expenses from investment operations;	(11,512)	(232)
EDITO A	510 573	245 021
EBITDA	518,762	345,921
TFRS 16 Lease payment effect	(102,019)	(75,281)
Adjusted EBITDA	416,743	270,640

.....